T1	intervention 0 11	Trastuzumab
T2	condition 39 56	clinical relapses
T3	No-of-participants 423 435	Seventy five
T4	eligibility 436 547	women with HER2 (-) breast cancer and detectable CK19 mRNA-positive CTCs before and after adjuvant chemotherapy
T5	intervention-participants 598 600	36
T6	control 605 616	observation
T7	control-participants 620 622	39
T8	outcome-Measure 764 797	3-year disease-free survival rate
T9	intervention-value 903 905	27
T10	intervention-participants 909 911	36
T11	intervention-value 913 916	75%
T12	outcome 924 949	became CK19 mRNA-negative
T13	control-value 962 967	seven
T14	control-participants 971 973	39
T15	control-value 975 980	17.9%
T18	outcome 1086 1094	relapses
T19	outcome 1300 1310	median DFS
T16	intervention-value 1062 1066	four
T20	intervention-value 1068 1071	11%
T17	control-value 1077 1079	15
T21	control-value 1081 1084	38%
